Lysosomal Therapies and Drug Delivery Strategies: An Overview

Advanced Drug Delivery Reviews, 2023

Effect of Acid Sphingomyelinase Deficiency in Type a Niemann‐Pick Disease on the Transport of Therapeutic Nanocarriers Across the Blood–Brain Barrier

Controlled Release Society, 2023

Altered Blood-Brain Barrier Transport of Nanotherapeutics in Lysosomal Storage Diseases

Journal of Controlled Release, 2022

Comparison Between Nanoparticle Encapsulation and Surface Loading for Lysosomal Enzyme Replacement Therapy

Int. J. Mol. Sci, 2022

Intertwined Mechanisms Define Transport of Anti-ICAM Nanocarriers Across the Endothelium and Brain Delivery of a Therapeutic Enzyme

Journal of Controlled Release, 2020

Combining Vascular Targeting and the Local First Pass Provides 100-Fold Higher Uptake of ICAM-1-Targeted vs Untargeted Nanocarriers in the inflamed Brain

Journal of Controlled Release, 2019

Enhanced Delivery and Effects of Acid Sphingomyelinase by ICAM-1-Targeted Nanocarriers in Type B Niemann-Pick Disease Mice

American Society of Cell and Gene Therapy—Molecular Therapy, 2017

ICAM-1-Targeted Nanocarriers Attenuate Endothelial Release of Soluble ICAM-1, an Inflammatory Regulator

Bioengineering & Translational Medicine, 2017

Targeting, Endocytosis, and Lysosomal Delivery of Active Enzymes to Model Human Neurons by ICAM-1-Targeted Nanocarriers

Pharmaceutical Research, 2015

Clathrin-Mediated Endocytosis is Impaired in Type A−B Niemann−Pick Disease Model Cells and Can Be Restored by ICAM-1-Mediated Enzyme Replacement

Molecular Pharmaceutics, 2014

Enhancing Biodistribution of Therapeutic Enzymes in Vivo by Modulating Surface Coating and Concentration of ICAM-1-Targeted Nanocarriers

Journal Biomedical Nanotechnology, 2014

ICAM-1 Engagement Modulates Sphingomyelinase and Ceramide, Supporting Uptake of Drug Carriers by the Vascular Endothelium

Arteriosclerosis, Thrombotic and Vascular Biology, 2013

Comparative Binding, Endocytosis, and Biodistribution of Antibodies and Antibody-Coated Carriers for Targeted Delivery of Lysosomal Enzymes to ICAM-1 Versus Transferrin Receptor

Journal of in herited Metabolism and Disease, 2013

Intra- and Trans-Cellular Delivery of Enzymes by Direct Conjugation with Non-Multivalent Anti-ICAM Molecules

Journal of Controlled Release, 2016

Enhanced Delivery of a-Glucosidase for Pompe Disease by ICAM-1-Targeted Nanocarriers: Comparative Performance of a Strategy for Three Distinct Lysosomal Storage Disorders

Nanomedicine, 2012

Effect of Flow on Endothelial Endocytosis of Nanocarriers Targeted to ICAM-1

Journal of Controlled Release, 2012

Enhanced Endothelial Delivery and Biochemical Effects of a-Galactosidase by ICAM-1-Targeted Nanocarriers for Fabry Disease

Journal of Controlled Release, 2011

Glycoengineered recombinant alpha1-antitrypsin results in comparable in vitro and in vivo activities to human plasma-derived protein

Biology, 2024

LeGenD: determining N-glycoprofiles using an explainable AI-leveraged model with lectin profiling

Biology, 2024

Correcting for sparsity and interdependence in glycomics by accounting for glycan biosynthesis

Nature Communications, 2021

Glyco-engineered CHO cell lines producing alpha-1-antitrypsin and C1 esterase inhibitor with fully humanized N-glycosylation profiles

Metabolic Engineering, 2019

A Markov chain model for N-linked protein glycosylation—towards a low-parameter tool for model-driven glycoengineering

Metabolic Engineering, 2016